Cancer biology is profoundly influenced by changes in the epigenome. Because the dynamic plasticity of the epigenome lends itself well to therapeutic manipulation, the past few years have witnessed an unprecedented investment in the development, characterization, and translation of targeted epigenetic therapies. In this review, I provide a broad context for recent developments that offer a greater understanding of how epigenetic regulators facilitate the initiation, maintenance, and evolution of cancer. I discuss newly developed epigenetic therapies and the cellular and molecular mechanisms that may govern sensitivity and resistance to these agents. I also review the rationale for future combination therapies involving existing and emerging epigenetic drugs.
癌症生物学深受表观基因组变化的影响。由于表观基因组的动态可塑性使其非常适合治疗性干预,过去几年中,针对表观遗传治疗的开发、表征和转化方面投入了前所未有的资金。在这篇综述中,我提供了近期发展的广阔背景,这些发展使人们更深入地理解表观遗传调控因子如何促进癌症的发生、维持和演变。我讨论了新开发的表观遗传治疗以及可能决定对这些药物敏感性和耐药性的细胞和分子机制。我还回顾了涉及现有和新兴表观遗传药物的未来联合治疗的理论依据。
The cancer epigenome: Concepts, challenges, and therapeutic opportunities